4296 completed, 1561 unknown, 1353 recruiting, 916 terminated. 9722 Phase 3, 1261 Phase 2.
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment Sildenafil - Cancer | Phase 2 / Phase 3 | Not yet recruiting | The University of Texas Medical Branch, Galveston | 30 | 2027-06-15 | 2026-05-11 |
| Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 465 | 2027-06-06 | 2026-06-18 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-11-02 |
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
Showing 20 of 9722. Sign in to see all of them.
Breast Neoplasms (1272) · Carcinoma, Non-Small-Cell Lung (815) · Prostatic Neoplasms (594) · Colorectal Neoplasms (520) · Multiple Myeloma (383) · Lung Neoplasms (360) · Neoplasm Metastasis (345) · Leukemia, Myeloid, Acute (329) · Carcinoma, Hepatocellular (317) · Stomach Neoplasms (301) · Ovarian Neoplasms (261) · Rectal Neoplasms (245) · Colonic Neoplasms (237) · Lymphoma (225)
Neoplasms by Site (6831) · Neoplasms by Histologic Type (3927) · Digestive System Diseases (1989) · Digestive System Neoplasms (1933) · Hemic and Lymphatic Diseases (1864) · Urogenital Diseases (1709) · Skin and Connective Tissue Diseases (1707) · Neoplasms, Glandular and Epithelial (1675) · Skin Diseases (1654) · Pathological Conditions, Signs and Symptoms (1532) · Urogenital Neoplasms (1499) · Immune System Diseases (1416) · Gastrointestinal Diseases (1358) · Genital Diseases (1358)
Cisplatin (770) · Carboplatin (604) · Paclitaxel (583) · Cyclophosphamide (556) · Radiotherapy (544) · Fluorouracil (484) · Docetaxel (471) · Gemcitabine (466) · Doxorubicin (396) · Capecitabine (391) · Dexamethasone (357) · Oxaliplatin (320) · Bevacizumab (302) · pembrolizumab (300) · Leucovorin (297)
Sun Yat-sen University (232) · Hoffmann-La Roche (203) · National Cancer Institute (NCI) (191) · Merck Sharp & Dohme LLC (190) · AstraZeneca (170) · Novartis Pharmaceuticals (150) · Fudan University (148) · European Organisation for Research and Treatment of Cancer - EORTC (133) · Alliance for Clinical Trials in Oncology (131) · Pfizer (115) · Bristol-Myers Squibb (101) · M.D. Anderson Cancer Center (97) · Children's Oncology Group (94) · GlaxoSmithKline (78) · Amgen (77)
United States (3592) · China (2532) · France (2077) · Canada (1950) · Germany (1872) · Italy (1855) · United Kingdom (1761) · Spain (1739) · Australia (1395) · Belgium (1368) · Poland (1312) · South Korea (1309) · Netherlands (1131) · Japan (1040) · Taiwan (962)
PMID 38979716, PMID 37185961, PMID 34037241, PMID 37146227, PMID 41276263, PMID 37407274, PMID 40135712, PMID 34350976, PMID 36306483, PMID 29522361, PMID 33337539, PMID 40207789, PMID 40966692, PMID 27238653, PMID 28410911, PMID 31150573, PMID 31268130, PMID 32691060, PMID 33242441, PMID 33356421, PMID 34795131, PMID 39121442, PMID 40341124, PMID 12049862, PMID 22689675, PMID 24722180, PMID 29272162, PMID 30679026, PMID 31378656, PMID 31395089, PMID 32450725, PMID 32632956, PMID 32816215, PMID 33270906, PMID 33300372, PMID 33526329, PMID 33538338, PMID 35170751, PMID 36884035, PMID 37419867, PMID 37505794, PMID 38320143, PMID 38620092, PMID 11981766, PMID 21997132, PMID 22417254, PMID 25592642, PMID 25881079, PMID 26101239, PMID 26373676
2023 (252), 2025 (99), 2018 (96), 2016 (94), 2014 (93), 2017 (88), 2015 (85), 2009 (65), 2019 (65), 2008 (64), U10CA180868 (64), 2005 (53), U10CA031946 (53), U10CA180820 (53), U10CA032102 (49)